ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

Conditions

• Greater Trochanteric Pain Syndrome
• Greater Trochanteric Pain Syndrome of Both Lower Limbs
• Lateral Hip Pain

Eligibility Criteria

Sex

ALL

Age

22 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Triamcinolone acetate — DRUG
  A single 40mg Triamcinolone dose, prepared as 1ml of steroid mixed with 4ml of saline, of which 3-5ml is injected.
• ReneuRx — DEVICE
  ReneuRx will be injected around the trochanteric branches of the femoral nerve.

Study Details

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Key Dates

First listed

May 5, 2026

Start date

Jul 27, 2026

Status verified

Aug 2026

Primary completion

Nov 1, 2027

Completion

Nov 1, 2029

Study Design

Enrollment

100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Triamcinolone acetate
  Corticosteroid injection
• Experimental: ReneuRx

Primary Outcome Measure

Primary Effectiveness [ Time Frame: 3-months post treatment ]

Central Contacts

• David Curd
  314-480-2244
  [email protected]

Locations (11)

Find similar trials in Sun City, AZ

Related Studies

• The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, Biomechanics, and Pain Intensity
  Not Yet Recruiting · Mayo Clinic · Glendale, Arizona
• Evaluation of TENEX for Greater Trochanteric Pain Syndrome (GTPS)
  Recruiting · Montefiore Medical Center · The Bronx, New York